<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11104554</article-id><article-id pub-id-type="pmc">2363438</article-id><article-id pub-id-type="pii">6691480</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1480</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mulatero</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>McClaren</surname><given-names>B R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mason</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oliver</surname><given-names>R T D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gallagher</surname><given-names>C J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Dept. of Medical Oncology, St Bartholomew's Hospital, London</aff><aff id="aff2"><label>2</label>Dept. of Clinical Oncology, Velindre Hospital, Cardiff, UK</aff><pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>83</volume><issue>12</issue><fpage>1612</fpage><lpage>1616</lpage><history><date date-type="received"><day>16</day><month>02</month><year>2000</year></date><date date-type="rev-recd"><day>25</day><month>07</month><year>2000</year></date><date date-type="accepted"><day>09</day><month>08</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A phase II study to evaluate the efficacy and toxicity of the combination of vinblastine, paclitaxel and cisplatin (PVC) in previously untreated patients with advanced transitional cell carcinoma. Chemotherapy naive patients with locally advanced or metastatic transitional cell carcinoma received the intravenous combination of paclitaxel 175&#x02009;mg/m<sup>2</sup> over three hours followed by cisplatin 70&#x02009;mg/m<sup>2</sup> over 3 hours on day 1 and vinblastine 3&#x02009;mg/m<sup>2</sup> as a bolus on days 1 and 8 on a 21-day cycle, to a maximum of 6 cycles. The day 8 vinblastine was omitted if the total neutrophil count was &#x0003c;1.0. 15 patients (13&#x02009;M, 2&#x02009;F) of median age 66 (54&#x02013;75) received a median of 5 cycles of treatment. There were two complete responses (13&#x00025;; 95&#x00025; CI 2&#x02013;40&#x00025;) and five partial responses (33&#x00025;; 95&#x00025; CI 12&#x02013;62&#x00025;), for an overall response rate of 46&#x00025; (95&#x00025; CI 21&#x02013;73&#x00025;). Responses occurred only in those with locally recurrent tumours and/or lymph nodes involved. Neutropenia at Grade 3&#x02013;4 occurred in 14 of 67 cycles (21&#x00025;) resulting in 7 episodes of neutropenic sepsis. Grade 3&#x02013;4 thrombocytopenia was not observed. Other Grade 3 toxicity included alopecia (10&#x02009;pts), diarrhoea (2&#x02009;pts), constipation resulting in bowel obstruction (2&#x02009;pts), nephrotoxicity (1&#x02009;pt), myalgic pain (1&#x02009;pt) and peripheral neuropathy (1&#x02009;pt). Six patients developed Grade 2 paraesthesia. The median time to progression was 6 months and the median survival was 11 months. The regimen PVC was both less effective against transitional cell carcinoma and less toxic than expected. This may reflect an inhibitory interaction between vinblastine and paclitaxel and this schedule cannot be recommended for further investigation. &#x000a9; 2000 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.org.uk">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>transitional cell</kwd><kwd>paclitaxel</kwd><kwd>vinblastine</kwd><kwd>cisplatin</kwd><kwd>schedule</kwd></kwd-group></article-meta></front></article>


